Personalized Neoantigen Peptide Vaccines for Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is to help the patient's immune system recognize and attack their cancer.

The study will enroll adult patients (20 years or older) who have solid tumors that meet specific stage-related criteria. These include advanced cancers that are resistant to prior treatments and early-stage cancers at high risk of recurrence, where there are no standard adjuvant therapies available.

Participants will receive:

* A personalized neoantigen peptide vaccine designed from the mutations in their tumor tissue.
* Poly-ICLC (Hiltonol), a substance that stimulates the immune system.
* An anti-PD-1 immune checkpoint inhibitor, a drug that helps the immune system stay active against cancer.

The vaccine and drugs will be given through multiple injections over several months. Blood samples and imaging will be used to monitor the immune response and how the cancer responds to treatment. Participants will be followed for up to 12 months.

This study does not include a placebo group. Every participant will receive the personalized vaccine along with the other therapies.

The primary objectives of this study are:

1. To assess whether the treatment is safe and tolerable.
2. To evaluate whether this approach helps control the cancer and can be combined with other standard treatments in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors

NCT06614140

Cancer Solid Tumor, Adult

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

NCT00874588

Non Small Cell Lung Cancer

COMPLETED PHASE1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210

Anatomic Stage IV Breast Cancer AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Cutaneous Melanoma +22 more

RECRUITING PHASE1

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

NCT05198752

Solid Tumor

UNKNOWN PHASE1

A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

NCT06610227

Advanced Solid Tumors

ACTIVE_NOT_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors Advanced Cancer Recurrent Cancer Neoantigen-Specific Immunotherapy Personalized Cancer Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Personalized Neoantigen Peptide Vaccine + Poly-ICLC + Anti-PD-1

Group Type EXPERIMENTAL

Personalized Neoantigen Peptide Vaccine

Intervention Type BIOLOGICAL

This is a personalized cancer vaccine made of 10-20 synthetic long peptides derived from the unique mutations (neoantigens) found in a patient's tumor. Each vaccine is custom-formulated based on whole exome and RNA sequencing of tumor and normal tissue. The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response. The intervention aims to induce T-cell responses against tumor-specific neoantigens. Vaccinations are given during priming and booster phases, with long-term follow-up and immune monitoring.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Personalized Neoantigen Peptide Vaccine

This is a personalized cancer vaccine made of 10-20 synthetic long peptides derived from the unique mutations (neoantigens) found in a patient's tumor. Each vaccine is custom-formulated based on whole exome and RNA sequencing of tumor and normal tissue. The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response. The intervention aims to induce T-cell responses against tumor-specific neoantigens. Vaccinations are given during priming and booster phases, with long-term follow-up and immune monitoring.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 20 years or older.
2. Language proficiency: Able to read and understand Thai clearly.
3. Consent: Willing to provide informed consent and sign a participation agreement.
4. Life expectancy: Estimated to be at least 6 months from the date of consent.
5. Eligibility from prior research: Must have participated in the SQK01-002A research project and have tumor tissue confirmed as suitable for neoantigen peptide vaccine production.
6. Performance status: ECOG performance status of 0-2 with stable organ function, no rapid disease progression, or impending organ failure.
7. Cancer diagnosis: Clinically and pathologically confirmed cancer diagnosis, with supporting radiological evidence.
8. Cancer stage-specific criteria:

i. Advanced cancer: Suitable for immune checkpoint inhibitors (ICIs) and shows resistance to prior therapies, with measurable lesions based on mRECIST1.1 criteria.

ii. Early-stage cancer: High recurrence risk despite prior surgery and/or radiotherapy, with no current adjuvant treatment standard.
9. Laboratory parameters:

i. Lymphocyte count ≥ 800 cells/μL. ii. Neutrophil count ≥ 1,500 cells/μL. iii. Platelet count ≥ 75,000 cells/μL. iv. AST ≤ 2.5 times the upper limit of normal (ULN). v. ALT ≤ 2.5 times ULN. vi. Total bilirubin ≤ 1.5 times ULN. vii. Serum creatinine ≤ 1.5 times ULN.
10. Consent to Avoid Pregnancy or Causing Pregnancy Under the Following Criteria i. Female participants not of reproductive age, defined as having undergone a hysterectomy and/or bilateral oophorectomy, experiencing continuous menopause for more than 12 months, or being over 60 years of age.

ii. Female participants of reproductive age must undergo a pregnancy test and have a confirmed negative result during the preparation phase and before the first day of vaccination. They must also consent to using contraception with an efficacy rate greater than 99%, as recommended by the principal investigator, throughout the study duration, including the preparation phase and follow-up, and up to 120 days after the final treatment.

iii. Male participants must consent to using contraception with an efficacy rate greater than 99%, as recommended by the principal investigator, throughout the study duration, including the preparation phase and up to 120 days after the final treatment.

Exclusion Criteria

1. History of hypersensitivity to peptide vaccines or related substances.
2. Autoimmune disease history.
3. Previous treatments that significantly suppress or impair immune function.
4. Refusal of current standard-of-care treatment.
5. Active brain or central nervous system metastases unless well-controlled with steroids ≤ 10 mg/day prednisolone.
6. Presence of more than one active cancer type.
7. Uncontrolled cardiac conditions, such as unstable angina or advanced heart failure (NYHA Class III/IV).

i. Participants with pacemakers may be eligible if stabilized for at least 1 month before vaccination.
8. Receipt of any other vaccines within 28 days before the first neoantigen peptide vaccine.
9. Participation in another clinical trial.
10. Use of immunosuppressive drugs or steroids \> 10 mg/day prednisolone (except inhaled/intranasal corticosteroids).
11. Pre-existing conditions that could compromise the efficacy or safety of the peptide vaccine.
12. Pregnancy or breastfeeding.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No